Under the terms of the agreement, Orion gains access to Abilita’s proprietary Enabled Membrane Protein (EMP™) technology for the discovery of novel antibody therapeutics to challenging GPCR (G ...
EMP-012 is under clinical development by Empirico and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) ...
Under the terms of the agreement, Orion gains access to Abilita’s proprietary Enabled Membrane Protein (EMP™) technology for the discovery of novel antibody therapeutics to challenging GPCR (G protein ...